1. Prognosis of Ocular Tuberculosis Following Long-Term Antitubercular Therapy.
- Author
-
Jiang T, Zhang X, Zhou M, Jiang R, and Chang Q
- Subjects
- Administration, Oral, Adrenal Cortex Hormones administration & dosage, Adrenal Cortex Hormones therapeutic use, Adult, Aged, Antitubercular Agents therapeutic use, China epidemiology, Choroiditis diagnosis, Choroiditis epidemiology, Choroiditis etiology, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Optic Nerve Diseases diagnosis, Optic Nerve Diseases epidemiology, Optic Nerve Diseases etiology, Panuveitis diagnosis, Panuveitis epidemiology, Panuveitis etiology, Prognosis, Retinal Vasculitis diagnosis, Retinal Vasculitis epidemiology, Retinal Vasculitis etiology, Retrospective Studies, Scleritis diagnosis, Scleritis epidemiology, Scleritis etiology, Treatment Outcome, Tuberculosis, Ocular complications, Tuberculosis, Ocular diagnosis, Uveitis, Anterior diagnosis, Uveitis, Anterior epidemiology, Uveitis, Anterior etiology, Uveitis, Intermediate diagnosis, Uveitis, Intermediate epidemiology, Uveitis, Intermediate etiology, Adrenal Cortex Hormones adverse effects, Antitubercular Agents adverse effects, Tuberculosis, Ocular drug therapy, Visual Acuity drug effects
- Abstract
Purpose: This study presents clinical features and prognosis after long-term (12-18 months) antitubercular therapy (ATT) in patients with ocular tuberculosis (OTB) in East China, an endemic area of tuberculosis. Methods: This retrospective study reviewed data from OTB patients treated at the Eye and ENT Hospital of Fudan University from 2008 to 2018. All the patients completed a minimum follow-up of 6 months after the cessation of ATT. Results: Sixty-six patients with OTB were studied. The ocular manifestations included retinal vasculitis (51.6%), choroiditis (24.2%), panuveitis (23.2%), intermediate uveitis (7.4%), scleritis (5.3%), anterior uveitis (2.1%), and optic neuropathy (1%). Except for two patients (ATT for 6 months), all other patients (64/66, 96.97%) received ATT for at least 12 months (6 patients for 12 months, 30 patients for 15 months, and 28 patients for 18 months). Treatment in conjunction with oral corticosteroids was used in 48 patients (72.7%). The average initial best-corrected visual acuity (BCVA) was 0.8 ± 0.64 (LogMAR), which improved to 0.31 ± 0.35 (LogMAR) at the last follow-up ( P < 0.05). The final BCVA was significantly associated with the initial BCVA and the duration of clinical symptoms. A complete remission of uveitis was achieved in 97% of the patients. Conclusions: This study observed a favorable prognosis with long-term ATT regimens. Patients with better baseline visual acuity and a shorter duration of clinical symptoms before diagnosis had a better prognosis.
- Published
- 2021
- Full Text
- View/download PDF